Specifications of a continual reassessment method design for phase I trials of combined drugs

被引:28
作者
Wages, Nolan A. [1 ]
Conaway, Mark R. [1 ]
机构
[1] Univ Virginia, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, VA USA
关键词
continual reassessment method; dose finding; maximum tolerated dose; phase I trials; partial ordering; drug combination; ADVANCED SOLID TUMORS; COMBINATIONS;
D O I
10.1002/pst.1575
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In studies of combinations of agents in phase I oncology trials, the dose-toxicity relationship may not be monotone for all combinations, in which case the toxicity probabilities follow a partial order. The continual reassessment method for partial orders (PO-CRM) is a design for phase I trials of combinations that leans upon identifying possible complete orders associated with the partial order. This article addresses some practical design considerations not previously undertaken when describing the PO-CRM. We describe an approach in choosing a proper subset of possible orderings, formulated according to the known toxicity relationships within a matrix of combination therapies. Other design issues, such as working model selection and stopping rules, are also discussed. We demonstrate the practical ability of PO-CRM as a phase I design for combinations through its use in a recent trial designed at the University of Virginia Cancer Center. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 18 条
  • [1] A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
    Berenson, James R.
    Yellin, Ori
    Patel, Ravi
    Duvivier, Herb
    Nassir, Youram
    Mapes, Russell
    Abaya, Christina DiLauro
    Swift, Regina A.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (03) : 1069 - 1075
  • [2] Designs for single- or multiple-agent phase I trials
    Conaway, MR
    Dunbar, S
    Peddada, SD
    [J]. BIOMETRICS, 2004, 60 (03) : 661 - 669
  • [3] Heyd JM, 1999, STAT MED, V18, P1307, DOI 10.1002/(SICI)1097-0258(19990615)18:11<1307::AID-SIM128>3.0.CO
  • [4] 2-X
  • [5] Korn EL, 1995, STAT MED, V15, P1799
  • [6] Model calibration in the continual reassessment method
    Lee, Shing M.
    Cheung, Ying Kuen
    [J]. CLINICAL TRIALS, 2009, 6 (03) : 227 - 238
  • [7] Non-parametric optimal design in dose finding studies
    O'Quigley, J
    Paoletti, X
    Maccario, J
    [J]. BIOSTATISTICS, 2002, 3 (01) : 51 - 56
  • [8] A stopping rule for the continual reassessment method
    O'Quigley, J
    Reiner, E
    [J]. BIOMETRIKA, 1998, 85 (03) : 741 - 748
  • [9] Retrospective Robustness of the Continual Reassessment Method
    O'Quigley, John
    Zohar, Sarah
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (05) : 1013 - 1025
  • [10] CONTINUAL REASSESSMENT METHOD - A PRACTICAL DESIGN FOR PHASE-1 CLINICAL-TRIALS IN CANCER
    OQUIGLEY, J
    PEPE, M
    FISHER, L
    [J]. BIOMETRICS, 1990, 46 (01) : 33 - 48